2018 CANADIAN TRANSPLANT SUMMIT ABSTRACTS

1. ABSTRACT SUBMISSION Guidelines

• The abstract submissions open February 23, 2018 and will close on  May 21st, 2018, 11:59:59PM ET. 
• There is no fee for submitting an abstract.
• All abstracts are to be received electronically. Paper or faxed submissions will not be accepted.
• Each abstract submitter must have an existing CST member profile or if a non-CST Member, create a Guest account to submit an abstract. 
  Note: If you submitted an abstract to the 2017 Scientific Meeting, you may use the same abstract account to submit for 2018.
• The abstract submitter will be considered as the primary author of the abstract.
• Submissions from Trainees, must include Supervisor's name and Supervisor's email address.
• It is the responsibility of the submitter to proofread the abstract submission and correct any errors prior to the abstract close date.
• An abstract submission may be revised online up until the abstract close date.
• Once the abstract deadline has passed, all requests for withdrawal must be submitted in writing by email to admin@cst-transplant.ca no later than June 29, 2018.
• Please note that there will be NO EXTENSION TO THE DEADLINE DATE. ***We will only consider 20 Late-Breaking Abstracts for the Poster Session Only - DEADLINE IS JUNE 18, 2018 AT 11:59P.M.EST***

Abstract Formatting

• Co-Authors' first name, last name and affiliation must be provided.
• The abstract must be organized in a structured format with sections for Background, Methods, Results and Conclusion and may not exceed 300 words in total.
• Do NOT include institutions in the abstract title, body or in the attachments to ensure a blinded review process.
• Prior to submission, the abstract submitter must ensure the abstract and all contents, including attachments fit on a single 8.5 x 11 page size.
• Minimum font size allowance is: 10 point
• Minimum Margin allowance is: Top 1”, Bottom: 0.5”, Left: 1”, Right: 1”

File Attachments

• Up to a total of three (3) Figures, Images, Tables and/or Charts may be included in JPEG, PDF or PNG format.
• Each image, figure, table and/or chart must be legible.
• Each file size cannot exceed more than 3 Megabytes per file.

LOGIN / CST Account - Guest Member Account

Note: Ensure to populate the Organization field, in your user profile, as this will be used as your Affiliation information BEFORE you create your Abstract. This information is automatically transferred to the Abstract system at the time of abstract creation. 

• Log IN - Existing CST Members/Registered Guest Members
• Create - Guest Member Account

2. Presentations

1) Oral Presentations

You will have a total of 10 minutes; 7 minutes of presentation, followed by 3 minutes for discussion.  Time limits will be strictly enforced.  Please be in the room for your session 10 minutes before the start time.  The chairpersons will start strictly on time and end on time.  Presentations times will not be changed.

We recommend that the background material be covered in 1-2 slides only.  All presenters are required to include a statement disclosing any conflict of interest related to your abstract as the first slide of your presentation.

2) Posters/E- Posters 

Instructions for Posters/E-Poster Presenters

Coming soon!

4. Presenter Disclosure  

Speaker Disclosure Slide

All presenters are required to include the Speaker Disclosure Slide in their presentations. If you do not include this in your presentation prior to arriving onsite, you will be required to insert it before your presentation. 

Generic and Trade Names

• Presentations must give a balanced view of therapeutic options.
• Faculty will be asked to use generic names to contribute to this impartiality.
• If trade names are used, those of several companies should be used rather than only that of a single supporting company.

Unlabeled Uses of Products

When an unlabeled use of a commercial product, or an investigational use not yet approved for any purpose is discussed during an educational activity the speaker should disclose that the product is not labeled for the use under discussion or that the product is still investigational.